Jean Hoffman-Censits, MD

Jean Hoffman-Censits, MD, medical oncologist, director, Multidisciplinary Genitourinary Oncology Center, Thomas Jefferson University Hospital, discusses the potential future of the investigational PD-L1 inhibitor atezolizumab. Hoffman-Censits says atezolizumab has recently undergone a phase II clinical trial for patients with bladder cancer who failed platinum-based chemotherapy.

Videos

Hoffman-Censits says atezolizumab has recently undergone a phase II clinical trial for patients with bladder cancer who failed platinum-based chemotherapy.

Dr. Jean Hoffman-Censits on the Future of Atezolizumab in Bladder Cancer

Jean Hoffman-Censits, MD, medical oncologist, director, Multidisciplinary Genitourinary Oncology Center, Thomas Jefferson University Hospital,  discusses the investigational PD-L1 inhibitor atezolizumab. Hoffman-Censits says outside of the first-line&nbsp;cisplatin-based chemotherapy in locally advanced unresectable bladder cancer tumors, there are currently no solutions for disease progression. She says patients who experienced progression were enrolled into a recent trial testing atezolizumab's efficacy against the malignancy.

Hoffman-Censits says outside of the first-line therapy of cisplatin-based chemotherapy in locally advanced unresectable bladder cancer tumors, there are currently no solutions for disease progression.

Jean Hoffman-Censits, MD | Authors

Articles

Dr. Jean Hoffman-Censits on the Future of Atezolizumab in Bladder Cancer

Dr. Jean Hoffman-Censits on the Results of a Phase II Trial Studying Atezolizumab in Bladder Cancer